3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
40
Lymphoma, Non-Hodgkin
39
Lymphoma, Follicular
24
Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Mantle-Cell
18
Lymphoma, B-Cell
10
Recurrence
9
Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
6
Hodgkin Disease
6
Multiple Myeloma
4
Hematologic Diseases
4
Lymphoma, T-Cell, Peripheral
3
Advanced Solid Tumor
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Interventions
Gemcitabine
2
10-propargyl-10-deazaaminopterin
2
tislelizumab
1
ontuxizumab
1
glofitamab
1
enasidenib
1
duvelisib
1
brincidofovir
1
belinostat
1
WW Domain-Containing Oxidoreductase
1
Vitamin B 12
1
Sensitivity and Specificity
1
MLN 8237
1
MAC-ST-001
1
Folic Acid
1
Fentanyl
1
Fenretinide
1
Commerce
1
Bendamustine Hydrochloride
1
(N(1),N(12))bis(ethyl)-6,7-dehydrospermine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immunoblastic Lymphadenopathy
×
Bendamustine Hydrochloride
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled